Navigation Links
Einstein scientists find crucial molecule involved in spread of breast cancer
Date:6/8/2011

June 8, 2011 (Bronx, NY) Researchers at Albert Einstein College of Medicine of Yeshiva University have identified a key player in the spread of breast cancer. The findings, published today in the online edition of Nature, identify a critical molecule that helps cancer spread beyond the primary tumor. The research highlights a potential new strategy against metastatic disease. The study's senior author is Jeffrey Pollard, Ph.D., professor of developmental and molecular biology and of obstetrics & gynecology and women's health at Einstein. He also holds the Louis Goldstein Swan Chair in Women's Cancer Research and is the deputy director of the Albert Einstein Cancer Center.

People rarely die from their primary (original) tumor. Instead, most cancer deaths occur because the cancer has spread, or metastasized, to other parts of the body. "By focusing on sites where cancer had spread, we were able to detect a molecule that stimulates metastasis," said Dr. Pollard. "This raises the possibility that metastasis could be kept from progressing or even prevented if the stimulating molecule could be blocked. This we achieved in mouse models of breast cancer."

Metastasis begins when cells break away from the primary tumor and gain the ability to move on their own. These cells invade nearby blood vessels (a process known as intravasation) and are carried by the bloodstream to other parts of the body. The bloodborne tumor cells then escape from vessels in a process known as extravasation. Once these tumor cells escape from the vessels, they seed new and deadly tumors that grow in these distant locations.

In previous studies, Dr. Pollard and his research team have shown that macrophages immune system cells whose functions include fighting infections actually promote the spread of cancer. His research has shown that macrophages not only assist tumor cells during both intravasation and extravasation but also help those wayward cells take root in their new locations and grow into metastatic tumors. In the current study, Dr. Pollard and colleagues investigated the process by which these macrophages are recruited to metastatic sites and subsequently promote tumor-cell extravasation, seeding and tumor growth.

Using models of human and mouse breast cancer, the researchers demonstrated that when breast tumor cells travel to the lung, these cells secrete CCL2, a chemokine molecule (i.e., one that attracts cells). CCL2 attracts immune cells called inflammatory monocytes -- in particular, those bearing receptors for CCL2, which then develop into macrophages. The monocytes and macrophages "invited" by CCL2 signaling then facilitate extravasation the critical step in metastasis in which bloodborne tumor cells cross the vessel wall and implant in nearby tissue. One way monocytes help tumor cells escape from blood vessels and cause metastasis, the Einstein researchers found, is by secreting vascular endothelial growth factor, or VEGF, a substance that makes blood vessels leaky at the site where tumor cells exit from them.

Once the tumor cells are seeded, inflammatory monocytes continue to flock to the metastatic site now attracted by CCL2 secreted not only by the tumor cells but also by nearby lung tissue that the tumor cells have targeted. In turn, these continuously recruited monocytes and the resultant macrophages promote the growth of the emerging metastatic tumor.

To confirm their findings, the researchers used anti-CCL2 antibodies to suppress CCL2 signaling in a mouse model of human metastasis with striking results. In lungs challenged with metastatic tumor cells, the anti-CCL2 antibodies inhibited the influx of inflammatory monocotyes and macrophages to the metastatic sites, and the number of metastatic sites that developed in the lungs was markedly reduced. In addition, the mice lived much longer when CCL2 signaling was blocked.

"These findings have potential implications for therapy, since in human breast cancer we know that CCL2 expression and macrophage infiltration are associated with poor prognosis and metastatic disease," said Dr. Pollard. "If we can develop ways to inhibit these processes, we might be able to slow or stop breast cancer from spreading."


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Einstein secures $11 million to continue research on brain aging and Alzheimers disease
2. Einstein Montefiore lung specialist to receive award for work with 9/11 rescue workers
3. Feinstein scientists identify abnormal disease pathway in dystonia
4. Susan Band Horwitz, Ph.D., of Einstein, receives lifetime achievement award in cancer research
5. Einstein-Montefiore researcher will test nanoparticles against pancreatic cancer
6. ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA
7. Feinstein Institute to share $5M US Department of Defense grant
8. Einstein scientist awarded $4 million to develop genetic strategy to combat tuberculosis
9. Einstein awarded NIH grant to study drug-resistant TB
10. NIH awards $10M to Einstein for diabetes research
11. Scientists create humanized mouse model for hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... it will soon begin franchising throughout the U.S. starting this spring. Current Meditation ... the practice of meditation mainstream. Current Meditation will be the first meditation concept ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only ... their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October ... the Virginia Mason Health System in Seattle since 2000. In addition to his role ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Curemark, LLC announced ... and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at ... already enrolling children across the United States. , “There are currently no approved ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thomas Vas-Don suffered ... exercise regime, the author was able to successfully recover. In “ Origin & Insertion ... for various sources on the principals of massage, anatomy , trigger points ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Genesis Healthcare Services ... The announcement was made by Bill Monast , ... Hartley and Nathan Feltman , executives with ... Healthcare Services, LLC. This acquisition helps ... provider of technology enabled durable medical equipment (DME) solutions ...
(Date:2/23/2017)... 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... proprietary products for the urology market, will release financial ... December 31, 2016 before the market open on Thursday, ... host a conference call and webcast to discuss its ... 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central ...
(Date:2/23/2017)... Nevro Corp. (NYSE: NVRO), a global medical device company that ... pain, today reported financial results for the three months and ... Accomplishment & Highlights: Achieved revenue of $228.5 ... as reported, over the prior year U.S. revenue ... the prior year International revenue of $55.2 ...
Breaking Medicine Technology: